Pharmacokinetic,Safety and Exploratory Efficacy of RECTIV® in Adolescents With Chronic Anal Fissure

Last updated: May 1, 2015
Sponsor: Forest Laboratories
Overall Status: Trial Not Available

Phase

4

Condition

Bowel Dysfunction

Rectal Disorders

Treatment

N/A

Clinical Study ID

NCT01920074
APT-NIT_S-PRO-M_PEDKPK1_E
  • Ages 12-16
  • All Genders

Study Summary

RECTIV® is an ointment containing 0.4% nitroglycerin (NTG) for the treatment of moderate to severe pain associated with chronic anal fissure approved in June 2011 by the US Food and Drug Administration (FDA) for adults. The purpose of this study is to assess the safety, pharmacokinetics, and exploratory efficacy of RECTIV® in adolescents

Eligibility Criteria

Inclusion

Key Inclusion Criteria:

  • Male or female ≥12 and <17 years of age

  • At least 1 anal fissure for a minimum of 3 weeks in duration

  • Anal fissure pain experienced over the last 24 hours at Screening and beforeenrollment

  • Patient (and parent or caregiver as appropriate) has provided written informed consent

Exclusion

Key Exclusion Criteria:

  • Current diagnosis of hemorrhoids

  • Hypersensitivity, allergy, or contraindication to nitroglycerin

  • History of hypertension and/or cardiovascular disease

  • History or current diagnosis of inflammatory bowel disease

  • History or current diagnosis of fistula(e)-in-ano or an anal abscess

  • Fibrotic anal stenosis

  • Previous anal surgery

  • Diagnosis of cancer

  • History of migraine or chronic headaches requiring treatment with analgesics

  • Pregnant or lactating female patients

  • Weight <36 kg

Study Design

Study Start date:
June 01, 2013
Estimated Completion Date:
April 30, 2015

Study Description

This is an open-label, multicenter study conducted in up to 10 sites in the United States. A total of 13 pediatric male or female patients age ≥12 to <17 years will be enrolled. The patients will administer a dose of Rectiv® twice daily to characterize the safety, pharmacokinetics , and exploratory efficacy of Nitroglycerin Ointment 0.4% (RECTIV® )over 5 days

Connect with a study center

  • Children's Hospital

    Los Angeles, California 90027
    United States

    Site Not Available

  • Advanced Medical Research Center

    Miami, Florida 33135
    United States

    Site Not Available

  • Arnold Palmer Hospital for Children

    Orlando, Florida 32806
    United States

    Site Not Available

  • Children's Hospital

    New Orleans, Louisiana 70118
    United States

    Site Not Available

  • Willis-Knighton Pediatric GI Specialist

    Shreveport, Louisiana 71118
    United States

    Site Not Available

  • Children's Mercy Hospital

    Kansas City, Missouri 64108
    United States

    Site Not Available

  • Sealy Urgent Care Center and Medical Clinic

    Sealy, Texas 77474
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.